JDRF T1D Fund
A venture philanthropy fund exclusively devoted to finding and funding the best early-stage T1D commercial opportunities.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed JDRF T1D Fund Information
Geographic Data
Address: 50 Milk Street
City: Boston
State: MA
Zip: 02109
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Facebook
Twitter
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
The JDRF T1D Fund (www.t1dfund.org) is a venture philanthropy fund exclusively devoted to finding and funding the best early-stage T1D commercial opportunities to accelerate the delivery of treatments, preventions, and cures to patients. It was created to solve a critical funding gap in the T1D drug and device development pipeline. Through partnerships with private capital, including venture capital, pharma and foundations, the T1D Fund anticipates that it will be able to attract substantially more private investment to the T1D field than occurs today. The T1D Fund will initially focus on artificial pancreas systems, metabolic control, beta cell replacement, prevention, and beta cell restoration therapies, with an exclusive priority on the best commercial opportunities. The T1D Fund will reinvest any realized gains into new investments to further its mission.
Contact Phone:
+16176342318
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 9/2020 | Sonoma Pharmaceuticals | Post-IPO Equity | 70M |
| 8/2021 | GentiBio | Series A | 157M |
| 9/2020 | Sonoma BioTherapeutics | Series A | 0 |
| 3/2018 | Bigfoot Biomedical | Series B | 0 |
| 10/2022 | Inversago Pharma | Series C | 0 |
| 4/2020 | Pandion Therapeutics | Series B | 80M |
| 3/2019 | Biolinq | Series A | 4.8M |
| 9/2019 | Veralox Therapeutics | Seed Round | 0 |
| 6/2022 | Code Biotherapeutics | Series A | 0 |
| 6/2021 | Veralox Therapeutics | Series A | 0 |
| 9/2020 | Inversago Pharma | Series B | 0 |
| 7/2018 | Inversago Pharma | Series A | 0 |
| 5/2020 | SQZ Biotech | Series D | 0 |
| 8/2021 | Sonoma BioTherapeutics | Series B | 0 |
| 3/2020 | Repertoire Immune Medicines | Venture Round | - |
| 10/2019 | IM Therapeutics | Series A | 10M |
| 6/2021 | Abata Therapeutics | Series A | 0 |
| 1/2017 | Provention Bio | Series A | 28.4M |
| 5/2023 | DiogenX | Series A | 0 |
| 3/2020 | Immunocore | Series B | 0 |
| 12/2017 | Bigfoot Biomedical | Series B | 0 |
| 6/2020 | DiogenX | Seed Round | 5.1M |
| 2/2021 | Seraxis | Series C | 40M |
| 8/2018 | SQZ Biotech | Series C | 0 |
| 8/2018 | Capillary Biomedical | Seed Round | 0 |
| 5/2017 | Tetragenetics | Venture Round | - |
| 2/2017 | GluSense | Grant | 2M |
| 7/2017 | Diasome Pharmaceuticals | Venture Round | 0 |
| 9/2018 | ImmusanT | Venture Round | - |
| 5/2020 | Kriya Therapeutics | Series A | 0 |
| 7/2020 | Enthera | Series A | 0 |
| 4/2021 | Code Biotherapeutics | Seed Round | 0 |
| 3/2017 | Semma Therapeutics | Venture Round | - |
| 11/2021 | Biolinq | Series B | 0 |
| 3/2022 | Jaguar Gene Therapy | Venture Round | - |
| 12/2017 | SQZ Biotech | Venture Round | - |
| 4/2020 | i2o Therapeutics | Seed Round | 4M |
| 11/2017 | Semma Therapeutics | Series B | 0 |
| 3/2017 | EGenesis | Series A | 0 |
| 5/2022 | Kriya Therapeutics | Series C | 0 |
| 7/2021 | Kriya Therapeutics | Series B | 0 |
| 6/2022 | Code Biotherapeutics | Series A | 0 |
| 5/2022 | Kriya Therapeutics | Series C | 0 |
| 3/2022 | Jaguar Gene Therapy | Venture Round | - |
| 11/2021 | Biolinq | Series B | 0 |
| 8/2021 | GentiBio | Series A | 0 |
| 8/2021 | Sonoma BioTherapeutics | Series B | 0 |
| 7/2021 | Kriya Therapeutics | Series B | 0 |
| 6/2021 | Abata Therapeutics | Series A | 0 |
| 6/2021 | Veralox Therapeutics | Series A | 0 |
| 4/2021 | Code Biotherapeutics | Seed Round | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
